Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of BIA 5-1058 in Healthy Adults
NCT03489005Phase 1Completed
- Sponsor
- BIAL
- Start
- Apr 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zamicastat in pulmonary arterial hypertension (PAH) and heart failure (HF) (4 arms), sponsored by BIAL. Primary endpoint: Time-matched change from baseline in placebo-adjusted QT interval corrected for heart rate based on an individual correction method at Day 1. Started Apr 2018; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)heart failure (HF)
Beyond the preview
Go deeper on NCT03489005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489005.